Study Evaluating the Safety and Pharmacokinetics of Ascending Single IV Doses of ERB-257

This study has been completed.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer Identifier:
First received: July 23, 2008
Last updated: April 24, 2009
Last verified: April 2009

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of ascending single IV doses of ERB-257 in healthy subjects

Condition Intervention Phase
Healthy Subjects
Drug: ERB-257
Other: placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Subjects

Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Primary Outcome Measures:
  • To evaluate the safety and tolerability of single ascending IV doses of ERB-257 administered to healthy subjects [ Time Frame: 4 days per group ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To evaluate the pharmacokinetics of single ascending IV doses of ERB-257 administered to healthy subjects [ Time Frame: 4 days per group ] [ Designated as safety issue: No ]

Enrollment: 48
Study Start Date: August 2008
Study Completion Date: November 2008
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ERB-257
7 IV single doses of ERB-257 will be given to 6 healthy subjects per group - 1,4, 15, 45, 90, 180, and 300 mg
Drug: ERB-257
Placebo Comparator: placebo
2 placebo subjects per group
Other: placebo


Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy men and women of non-childbearing potential between the ages of 18 and 50.
  2. Body mass index (BMI) in the range of 18.0 to 30.0 kg/m2 and body weight greater than or equal to 50 kg2.
  3. Have a high probability for compliance with and completion of the study.

Exclusion Criteria:

  1. Presence or history of any disorder that may prevent the successful completion of the study.
  2. Acute disease state (eg, nausea, vomiting, fever, or diarrhea) within 7 days before study day 1.
  Contacts and Locations
Please refer to this study by its identifier: NCT00722501

United States, Pennsylvania
Trial Manager
Philadelphia, Pennsylvania, United States, 19148
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
  More Information

No publications provided

Responsible Party: Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth Identifier: NCT00722501     History of Changes
Other Study ID Numbers: 3252K1-1000
Study First Received: July 23, 2008
Last Updated: April 24, 2009
Health Authority: United States: Food and Drug Administration processed this record on April 17, 2014